67,016 Shares in Entrada Therapeutics, Inc. $TRDA Bought by Nuveen LLC

Key Points

• Nuveen LLC acquired 67,016 shares of Entrada Therapeutics, Inc. (NASDAQ: TRDA), valued at approximately $606,000, during the first quarter, bringing their total ownership to about 0.18% of the company.
• Multiple institutional investors, including Janus Henderson Group PLC and Dimensional Fund Advisors LP, significantly increased their stakes in Entrada Therapeutics during the fourth quarter.
• Wall Street analysts have mixed opinions on Entrada Therapeutics, with one report downgrading the stock to a "sell" while another maintains a "buy" rating and a price target of $20.00.

Nuveen LLC acquired a new stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 67,016 shares of the company's stock, valued at approximately $606,000. Nuveen LLC owned 0.18% of Entrada Therapeutics at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Allspring Global Investments Holdings LLC boosted its position in Entrada Therapeutics by 53.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 17,020 shares of the company's stock worth $149,000 after acquiring an additional 5,896 shares during the period. BNP Paribas Financial Markets acquired a new position in Entrada Therapeutics in the 4th quarter valued at approximately $57,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Entrada Therapeutics by 152.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,750 shares of the company's stock valued at $618,000 after buying an additional 21,594 shares during the period. Deutsche Bank AG grew its stake in Entrada Therapeutics by 55.5% in the fourth quarter. Deutsche Bank AG now owns 21,740 shares of the company's stock valued at $376,000 after acquiring an additional 7,757 shares during the period. Finally, Mackenzie Financial Corp bought a new stake in Entrada Therapeutics during the fourth quarter worth about $251,000. Hedge funds and other institutional investors own 86.39% of the company's stock.

Insider Buying and Selling at Entrada Therapeutics

In other news, Director Kush Parmar sold 27,000 shares of the company's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total transaction of $202,500.00. Following the completion of the transaction, the director directly owned 1,093,313 shares of the company's stock, valued at approximately $8,199,847.50. This represents a 2.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Ventures V. L.P. 5Am sold 6,935 shares of Entrada Therapeutics stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $7.50, for a total value of $52,012.50. Following the completion of the sale, the insider directly owned 1,093,313 shares of the company's stock, valued at approximately $8,199,847.50. This represents a 0.63% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 254,000 shares of company stock valued at $1,782,000. 7.59% of the stock is owned by insiders.

Entrada Therapeutics Stock Performance

TRDA traded down $0.08 during midday trading on Monday, reaching $5.21. 159,462 shares of the company were exchanged, compared to its average volume of 155,611. The stock's 50-day simple moving average is $6.06 and its 200 day simple moving average is $7.89. Entrada Therapeutics, Inc. has a one year low of $4.93 and a one year high of $21.79. The stock has a market capitalization of $198.19 million, a P/E ratio of -2.92 and a beta of -0.13.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.18). Entrada Therapeutics had a negative net margin of 92.30% and a negative return on equity of 17.81%. The company had revenue of $1.98 million for the quarter, compared to analysts' expectations of $8.17 million. On average, research analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on TRDA shares. Wall Street Zen cut Entrada Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Zacks Research upgraded shares of Entrada Therapeutics to a "hold" rating in a report on Friday, August 8th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Entrada Therapeutics in a research report on Tuesday, May 20th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $25.67.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.